Rekvina Laboratories Ltd.

As of June 30, 2026, Rekvina Laboratories Ltd. carries a market capitalization of 206.66M, placing it among publicly traded companies globally. Its enterprise value stands at 206.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Rekvina Laboratories Ltd. has 6.03M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 10.69 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 206.66M versus a market cap of 206.66M, with the gap driven by net debt and cash on the balance sheet.

As of the close on October 23, 2026, Rekvina Laboratories Ltd.'s stock has gained approximately 1129.78% over the past 52 weeks. The 50-day moving average sits at 50.98, while the 200-day moving average is 33.98.

Over the twelve months ended June 30, 2026, Rekvina Laboratories Ltd. generated 19.33M in revenue and converted that into -3.40M in net income, yielding earnings per share of -0.57. EBITDA reached -3.40M, while operating income came in at -3.40M.

Over the twelve months ended June 30, 2026, Rekvina Laboratories Ltd. posted a gross margin of 4.96, reflecting its pricing power and cost economics. The operating margin of -17.60 and net profit margin of -17.58 provide insight into operational efficiency.

Rekvina Laboratories Ltd.'s most recent stock split took place on April 30, 2014 with a 1:2 split ratio.